ZA201106419B - Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid - Google Patents

Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid

Info

Publication number
ZA201106419B
ZA201106419B ZA2011/06419A ZA201106419A ZA201106419B ZA 201106419 B ZA201106419 B ZA 201106419B ZA 2011/06419 A ZA2011/06419 A ZA 2011/06419A ZA 201106419 A ZA201106419 A ZA 201106419A ZA 201106419 B ZA201106419 B ZA 201106419B
Authority
ZA
South Africa
Prior art keywords
barbituric acid
composition
brain delivery
improved bioavailability
diphenyl
Prior art date
Application number
ZA2011/06419A
Other languages
English (en)
Inventor
Daniella Gutman
Daniel Moros
Howard Rutman
Avraham Yacobi
Barrie Levitt
Original Assignee
Taro Pharma Ind
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taro Pharma Ind filed Critical Taro Pharma Ind
Publication of ZA201106419B publication Critical patent/ZA201106419B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/60—Three or more oxygen or sulfur atoms
    • C07D239/62—Barbituric acids
    • C07D239/64—Salts of organic bases; Organic double compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ZA2011/06419A 2004-08-10 2011-09-01 Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid ZA201106419B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60032704P 2004-08-10 2004-08-10

Publications (1)

Publication Number Publication Date
ZA201106419B true ZA201106419B (en) 2012-05-30

Family

ID=34942111

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/06419A ZA201106419B (en) 2004-08-10 2011-09-01 Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid

Country Status (14)

Country Link
EP (2) EP1625848A1 (https=)
JP (2) JP2008509914A (https=)
KR (2) KR20120130256A (https=)
CN (2) CN101052403A (https=)
AT (1) ATE510541T1 (https=)
AU (1) AU2005280419B2 (https=)
BR (1) BRPI0513337A (https=)
CA (1) CA2576832C (https=)
IL (1) IL181247A (https=)
MX (1) MX2007001655A (https=)
NZ (1) NZ553653A (https=)
SG (1) SG163500A1 (https=)
WO (1) WO2006026095A2 (https=)
ZA (1) ZA201106419B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7683071B2 (en) 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
WO2004052350A2 (en) 2002-12-11 2004-06-24 Taro Pharmaceutical Industries Limited Method of treating movement disorders using barbituric acid derivatives
EP1625848A1 (en) * 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid
CN102863579B (zh) * 2012-09-14 2014-02-05 东南大学 一种巴比妥酸螯合树脂及其制备方法和应用
KR102162003B1 (ko) 2014-04-14 2020-10-06 삼성전자주식회사 무선 네트워크 연결 제어 방법 및 장치
KR101822417B1 (ko) * 2017-06-14 2018-01-29 주식회사 청도제약 인간의 체액에서 산화 스트레스를 측정하기 위한 방법
GB202100352D0 (en) * 2021-01-12 2021-02-24 Balticgruppen Bio Ab New methods

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2119701A (en) * 1934-06-29 1938-06-07 Winthrop Chem Co Inc Alkoxyalkyl mercury nitrogen compounds
IL69722A (en) * 1983-09-14 1986-09-30 Taro Pharma Ind Oxopyrimidine derivatives and pharmaceutical compositions containing them
DE4433764A1 (de) * 1994-09-22 1996-03-28 Asta Medica Ag Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
US6093820A (en) * 1997-10-02 2000-07-25 Taro Pharmaceutical Industries Ltd. Method and reagents for N-alkylating ureides
WO2002007729A1 (en) * 2000-07-26 2002-01-31 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US6756379B2 (en) * 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
EP1485101A4 (en) * 2002-01-30 2006-04-12 Taro Pharma Ind NON-SURFACTANT BARBITIC ACID DERIVATIVES
WO2004052350A2 (en) * 2002-12-11 2004-06-24 Taro Pharmaceutical Industries Limited Method of treating movement disorders using barbituric acid derivatives
EP1625848A1 (en) * 2004-08-10 2006-02-15 Taro Pharmaceuticals North America, Inc. Composition and method for enhanced delivery of 5,5-diphenyl barbituric acid

Also Published As

Publication number Publication date
EP1625848A1 (en) 2006-02-15
IL181247A0 (en) 2007-07-04
EP1781294A2 (en) 2007-05-09
MX2007001655A (es) 2007-04-23
CN101052403A (zh) 2007-10-10
HK1108313A1 (en) 2008-05-02
CA2576832A1 (en) 2006-03-09
EP1781294B1 (en) 2011-05-25
CA2576832C (en) 2013-06-11
BRPI0513337A (pt) 2008-05-06
WO2006026095A2 (en) 2006-03-09
IL181247A (en) 2012-05-31
AU2005280419B2 (en) 2010-09-23
AU2005280419A1 (en) 2006-03-09
SG163500A1 (en) 2010-08-30
KR20120130256A (ko) 2012-11-29
EP1781294A4 (en) 2007-12-26
CN102512422A (zh) 2012-06-27
JP2008509914A (ja) 2008-04-03
KR20070074549A (ko) 2007-07-12
NZ553653A (en) 2010-06-25
ATE510541T1 (de) 2011-06-15
JP2013177442A (ja) 2013-09-09
WO2006026095A3 (en) 2007-02-01

Similar Documents

Publication Publication Date Title
ZA201106419B (en) Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
MY134422A (en) Platinum derivative pharmaceutical formulations.
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
WO2007002516A3 (en) Improved dosage forms for movement disorder treatment
TW200635903A (en) Therapeutic agents
HRP20041179A2 (en) Prodrugs of excitatory amino acids
PL370529A1 (en) Use of 2-oxo-1-pyrrolidine derivatives for the preparation of a drug
IL192287A0 (en) Pharmaceutical compositions and methods for use
IL162515A0 (en) Substituted diketopiperazines as oxytocin antagonists
MXPA05011432A (es) Uso de dipiridamol o mopidamol para tratamiento y prevencion de enfermedades trombo-embolicas y desordenes originados por formacion excesiva de trombina y/o por expresion elevada de receptores de trombina.
SG178942A1 (en) Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same
TW200509933A (en) Therapeutic agents
TW200633986A (en) Therapeutic agents
MY142431A (en) Oxadiazolones, processes for their preparation and their use as pharmaceuticals
ATE366107T1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
TW200631956A (en) Azabenzoxazoles for the treatment of CNS disorders
TW200621788A (en) Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase Iε
WO2005046605A3 (en) Compositions and methods of treating neurological diseases
BRPI0410651A (pt) composto, composição farmacêutica, e, métodos para tratar ou prevenir cáncer, degeneração macular do tipo úmida ou artrite reumatóide, vascularização aberrante, nìveis de cobre em excesso, obesidade e doença neurodegenerativa em um paciente
MXPA05008990A (es) Derivados de acido alcanoico sustituido con cicloalquilo, metodos para su produccion y su uso como medicamentos.
AU8844301A (en) Method for treating the central nervous system by administration of igf structural analogs
TW200510331A (en) Heteroaryl-substituted imidazole derivatives
MXPA05007253A (es) Sales novedosas de derivados anticonvulsivantes.
MX2009005676A (es) Dialquilamino alquil esteres de pivagabina como medicamentos para el tratamiento de alteraciones del sistema nervioso central.
TW200727904A (en) Method of administration for 5-(2-chlorophenyl)-1,2-dihydro-7-fluoro-8-methoxy-3-methyl-pyrazolo[3,4-b][1,4]benzodiazepine